ArticleEvidence-based complementary and alternative medicine : eCAM2020
Therapeutic Effect of
Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Self-regulating neohesperidin/silk fibroin composite aerogel for enhanced wound healing via pH-responsive release.Materials today. Bio · 2026Article
- Activation of µ-δ Opioid Receptor Heteromer Attenuates Chemotherapy-Induced Neuropathic Pain in Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Progress and Prospects of Transdermal Treatment of Allergic Skin Diseases with Natural Drugs based on Nanotechnology.AAPS PharmSciTech · 2025Review
- Cimifugin Alleviates Chronic Constriction Injury of the Sciatic Nerve by Suppressing Inflammatory Response and Schwann Cell Apoptosis.Cell biochemistry and biophysics · 2025Article
- Regulation of transient receptor potential ankyrin 1 by traditional Chinese medicine drugs and their active ingredients.Frontiers in pharmacology · 2025Review
- Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: review of molecular pharmacology actiona.The Korean journal of pain · 2024Review
- Review
- An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives.Frontiers in pharmacology · 2024Review
- Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis.Pharmaceutics · 2023Review
- Ferulic acid alleviates sciatica by inhibiting neuroinflammation and promoting nerve repair via the TLR4/NF-κB pathway.CNS neuroscience & therapeutics · 2023Article
- Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation.Frontiers in cardiovascular medicine · 2023Article
- Central and peripheral analgesic active components of triterpenoid saponins fromFrontiers in pharmacology · 2023Article
- Identification of pyroptosis‑related genes in neuropathic pain based on bioinformatics analysis.Experimental and therapeutic medicine · 2023Article
- Therapeutic effect of paeoniflorin on chronic constriction injury of the sciatic nerve via the inhibition of Schwann cell apoptosis.Phytotherapy research : PTR · 2022Article
- Neuropeptide Y in the amygdala contributes to neuropathic pain-like behaviors in ratsBioengineered · 2022Article
- Kaempferol exerts a neuroprotective effect to reduce neuropathic pain through TLR4/NF-ĸB signaling pathway.Phytotherapy research : PTR · 2022Article
- Ginsenoside Rh2 Ameliorates Neuropathic Pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis.Molecular pain · 2022Article
- Protective effect of 18β-glycyrrhetinic acid against HExperimental and therapeutic medicine · 2021Article
- Higenamine Attenuates Neuropathic Pain by Inhibition of NOX2/ROS/TRP/P38 Mitogen-Activated Protein Kinase/NF-ĸB Signaling Pathway.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHederagenin is one of the main components of
methodsFirstly, we obtained pain-related targets and performed KEGG pathway enrichment on these targets. Then, 42 SD rats were separated randomly into six groups: sham operation group, CCI group, pregabalin group, mecobalamin group,
resultsRats in the CCI group were more sensitive to hyperalgesia and allodynia to mechanical and thermal stimuli, as well as cold pain. All four drugs could relieve these pains. Pregabalin, mecobalamin, and
conclusion
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.